Arcellx ACLX Q4 2025 Earnings NarrowerthanExpected Loss Highlights Cost Discipline Amid PreRevenue Stage Marvell Technology Q1 2026 Earnings Slight EPS Miss Overshadowed by Positive Stock Reaction ZBIO Q1 2026 Earnings EPS Beat Offers Little Lift as No Revenue and Stock Decline Persist CVNA Q1 2026 Earnings EPS Surpasses Estimates Despite Revenue Uncertainty Upstream Bio Q1 2026 Earnings NarrowerthanExpected Loss Amid Clinical Progress AS Q1 2026 Earnings EPS Surpasses Estimates by Over 21